<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Interleukin 1 inhibitors: Biology, principles of use, and adverse events</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Interleukin 1 inhibitors: Biology, principles of use, and adverse events</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Interleukin 1 inhibitors: Biology, principles of use, and adverse events</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Peter A Nigrovic, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">James R O'Dell, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Siobhan M Case, MD, MHS</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Oct 12, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H620493584"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Interleukin (IL) 1 is a highly potent proinflammatory mediator that is important in immune defense and in immune-mediated disease. Three pharmacologic inhibitors (sometimes termed blockers) of IL-1 are commercially available: <a class="drug drug_general" data-topicid="9246" href="/d/drug information/9246.html" rel="external">anakinra</a>, <a class="drug drug_general" data-topicid="8906" href="/d/drug information/8906.html" rel="external">canakinumab</a>, and <a class="drug drug_general" data-topicid="9483" href="/d/drug information/9483.html" rel="external">rilonacept</a>  (<a class="graphic graphic_table graphicRef128320" href="/d/graphic/128320.html" rel="external">table 1</a>).</p><p>General considerations regarding the use of these agents are presented here. The use of these agents for the treatment of specific inflammatory and autoimmune diseases is described in detail separately. (See  <a class="medical medical_review" href="/d/html/5585.html" rel="external">"Cryopyrin-associated periodic syndromes and related disorders"</a> and  <a class="medical medical_review" href="/d/html/6400.html" rel="external">"Systemic juvenile idiopathic arthritis: Treatment"</a> and  <a class="medical medical_review" href="/d/html/5595.html" rel="external">"Treatment of adult-onset Still's disease"</a> and  <a class="medical medical_review" href="/d/html/5580.html" rel="external">"Tumor necrosis factor receptor-1 associated periodic syndrome (TRAPS)", section on 'Management'</a> and  <a class="medical medical_review" href="/d/html/5955.html" rel="external">"Hyperimmunoglobulin D syndrome: Management"</a> and  <a class="medical medical_review" href="/d/html/2574.html" rel="external">"Management of familial Mediterranean fever"</a> and  <a class="medical medical_review" href="/d/html/1666.html" rel="external">"Treatment of gout flares"</a>.)</p><p class="headingAnchor" id="H4082387705"><span class="h1">OVERVIEW OF IL-1 BIOLOGY</span></p><p class="headingAnchor" id="H4202572495"><span class="h2">Major components</span><span class="headingEndMark"> — </span>Interleukin (IL) 1 encompasses two distinct cytokines, IL-1alpha and IL-1beta, that signal via the same receptor, IL-1 receptor, type 1 (IL-1R1) [<a href="#rid1">1</a>]. A related IL-1 family member, IL-1 receptor antagonist (IL-1ra), serves as an inhibitor that competes with both cytokines for binding to the receptor. IL-1R1 is expressed by most immune and nonimmune cells, accounting for the broad proinflammatory impact of IL-1.</p><p>A second IL-1 receptor, IL-1R2, serves as a nonsignaling decoy receptor both in membrane-bound and soluble forms, especially for IL-1beta. IL-1beta (evolutionarily older than IL-1alpha) is more important than IL-1alpha in most systemic inflammatory diseases.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>IL-1beta</strong> – IL-1beta is produced predominantly by myeloid cells such as macrophages, neutrophils, and mast cells. Release of IL-1beta is closely regulated. In most contexts, it is not expressed constitutively but is induced by proinflammatory stimuli such as lipopolysaccharides that turn on transcription of the IL-1beta gene. The resulting 41 kDa pro-IL-1beta is inert until cleaved by the inflammasome, a protein complex that activates caspase-1, also called IL-1 converting enzyme.</p><p></p><p class="bulletIndent1">Caspase-1 cleaves pro-IL-1beta into active 17 kDa IL-1beta, which is released by cells through mechanisms including cytoplasmic membrane pores formed by gasdermin D, another protein cleaved by the inflammasome. At least six distinct inflammasomes are known, varying by assembly trigger and tissue distribution; aberrant activation of these complexes results in a set of autoinflammatory syndromes known as the inflammasomopathies. (See  <a class="medical medical_review" href="/d/html/122506.html" rel="external">"Autoinflammatory diseases mediated by inflammasomes and related IL-1 family cytokines (inflammasomopathies)"</a>.)</p><p></p><p class="bulletIndent1">IL-1beta can also be cleaved through inflammasome-independent pathways. For example, activated T cells induce macrophages to process pro-IL-1beta to active IL-1beta through caspase 8 [<a href="#rid2">2,3</a>]. Thus, IL-1beta can be produced by antigen-driven immune activation as well as antigen-independent processes such as autoinflammatory diseases. (See  <a class="medical medical_review" href="/d/html/5597.html" rel="external">"The autoinflammatory diseases: An overview"</a> and  <a class="medical medical_review" href="/d/html/122506.html" rel="external">"Autoinflammatory diseases mediated by inflammasomes and related IL-1 family cytokines (inflammasomopathies)"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>IL-1alpha</strong> – IL-1alpha arose from IL-1beta through a gene duplication event and subsequent functional specialization [<a href="#rid4">4</a>]. Resulting differences in protein sequence between these cytokines result in for important functional differences. Further, whereas IL-1beta is expressed primarily by immune cells, IL-1alpha is expressed constitutively in keratinocytes in the skin, in epithelium of lung and gut, and by platelets and megakaryocytes; myeloid cells express IL-1alpha when activated [<a href="#rid1">1,5</a>]. IL-1alpha also can be expressed on the cell membrane, activating neighboring cells via contact as well as through microvesicles budded from the cell surface [<a href="#rid6">6</a>].</p><p></p><p class="bulletIndent1">Like IL-1beta, IL-1alpha is synthesized as a pro-form, but pro-IL-1alpha is functional, activating cells via IL-1R1 with a potency approximately half that of IL-1beta and of cleaved IL-1alpha [<a href="#rid7">7</a>]. Pro-IL-1alpha includes protein-protein interaction domains relevant for its activity, including a nuclear localization sequence that enables it to function as a transcription factor [<a href="#rid1">1,4</a>]. During apoptosis, chromatin binding prevents escape of pro-IL-1alpha into the cellular milieu, whereas necrotic cell death releases the cytokine into the environment to mediate tissue inflammation [<a href="#rid1">1,8</a>]. Taken together, these functions translate into a role for IL-1alpha primarily in local inflammatory responses as a tissue-restricted danger signal (an "alarmin" function), whereas IL-1beta plays a more prominent role in systemic disease because of its release by circulating and tissue-infiltrating inflammatory cells as well as by resident macrophages and mast cells.</p><p></p><p class="headingAnchor" id="H477123004"><span class="h2">IL-1 function</span><span class="headingEndMark"> — </span>Interleukin (IL) 1 participates in both innate and adaptive immune function. Engagement of IL-1R1 by IL-1alpha or IL-1beta engages a membrane-bound coreceptor, IL-1 receptor accessory protein (IL-1RAcP)  (<a class="graphic graphic_figure graphicRef128248" href="/d/graphic/128248.html" rel="external">figure 1</a>), and the trimolecular IL-1/IL-1R1/IL-1RAcP complex initiates an intracellular kinase-dependent signaling process mediated by the adaptor protein MyD88 (also termed myeloid differentiation primary response 88), resulting in a wide range of cell-activation events, including new gene transcription mediated through the nuclear factor kappa-light-chain-enhancer of activated B cells (NFkB) pathway.</p><p>Downstream effects depend upon the responding lineage and may include production of cytokines such as IL-6 (and IL-1beta itself) and upregulation of adhesion molecules on leukocytes and endothelial cells to promote cell migration. IL-1 is the major endogenous pyrogen, triggering fever via the hypothalamus [<a href="#rid9">9</a>]. Beyond these acute effects, IL-1 skews the differentiation of T cells toward proinflammatory T helper 17 (Th17) cells, while also aiding the function of CD4+ and CD8+ T cells and promoting effector T cell cytokine production [<a href="#rid10">10-13</a>].</p><p class="headingAnchor" id="H2416348647"><span class="h1">PRETREATMENT TESTING</span><span class="headingEndMark"> — </span>We perform the following testing and evaluation before initiating treatment with an interleukin (IL) 1 inhibitor:</p><p class="bulletIndent1"><span class="glyph">●</span>Baseline laboratory studies should include a complete blood count with differential, electrolytes and creatinine, hepatic transaminases, and bilirubin. Additional testing may be required for assessment of disease activity, which varies depending upon the disorder being treated.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Females of reproductive age should be screened for pregnancy and counseled appropriately with respect to reproductive risk. Additional information regarding risk during pregnancy and breastfeeding is provided separately, including in the respective drug information topics for each agent. (See  <a class="medical medical_review" href="/d/html/7998.html" rel="external">"Safety of rheumatic disease medication use during pregnancy and lactation", section on 'Ixekizumab'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Screening for latent tuberculosis, hepatitis B, and hepatitis C is generally performed prior to initiating treatment. However, IL-1 inhibition does not appear to complicate these conditions [<a href="#rid14">14</a>]. Thus, when treatment is urgently indicated, it is reasonable to initiate therapy while awaiting screening results.</p><p></p><p class="headingAnchor" id="H3358448533"><span class="h1">SPECIFIC AGENTS</span></p><p class="headingAnchor" id="H1357852890"><span class="h2">Anakinra</span></p><p class="headingAnchor" id="H4151370345"><span class="h3">Structure and mechanism of action</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9246" href="/d/drug information/9246.html" rel="external">Anakinra</a> is recombinant interleukin (IL) 1 receptor antagonist (IL-1ra)  (<a class="graphic graphic_figure graphicRef128248" href="/d/graphic/128248.html" rel="external">figure 1</a>). At 153 amino acids in length (17 kDa), it differs from endogenous IL-1ra by the inclusion of an additional methionine at the amino terminus; it is otherwise identical to the endogenous nonglycosylated variant of IL-1ra and appears to be a pure receptor antagonist [<a href="#rid15">15-17</a>]. IL-1ra binds IL-1 receptor, type 1 (IL-1R1) with an affinity equivalent to IL-1alpha and IL-1beta but does not recruit IL-1 receptor accessory protein (IL-1RAcP) and so fails to initiate a signal [<a href="#rid18">18</a>]. Less than 5 percent of surface IL-1R1 must be bound by the cytokine to elicit an activating signal, so IL-1ra must be present in substantial (&gt;100-fold) excess to serve as an effective competitor [<a href="#rid19">19</a>].</p><p>While antidrug antibodies may form with <a class="drug drug_general" data-topicid="9246" href="/d/drug information/9246.html" rel="external">anakinra</a> use, most are non-neutralizing and do not appear to block efficacy or correlate with adverse events, although neutralizing antidrug antibodies have been reported in some patients exhibiting treatment nonresponse [<a href="#rid20">20,21</a>]. Unlike the other IL-1 inhibitors, anakinra penetrates the blood-brain barrier and achieves antiinflammatory concentrations in the brain [<a href="#rid22">22,23</a>].</p><p class="headingAnchor" id="H1649632718"><span class="h3">Indications</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9246" href="/d/drug information/9246.html" rel="external">Anakinra</a> is approved by the US Food and Drug Administration (FDA) for patients with moderate to severe rheumatoid arthritis and for patients with cryopyrin-associated periodic syndromes (CAPS) [<a href="#rid24">24</a>]. The European Medicines Agency has approved anakinra for these indications and for Still's disease (encompassing both systemic juvenile idiopathic arthritis [sJIA] and adult-onset Still's disease) [<a href="#rid25">25</a>]. Other indications for which anakinra is routinely employed include idiopathic recurrent pericarditis resistant to <a class="drug drug_general" data-topicid="9293" href="/d/drug information/9293.html" rel="external">colchicine</a> [<a href="#rid26">26</a>], autoinflammatory diseases without established genetic diagnosis [<a href="#rid27">27</a>], and gout flares, especially in patients with contraindications to conventional therapy with nonsteroidal antiinflammatory drugs (NSAIDs), glucocorticoids, and colchicine [<a href="#rid28">28-30</a>]. The uses of anakinra for these and other indications and the evidence supporting such uses are described separately in the topic reviews on treatment of these disorders. (See  <a class="medical medical_review" href="/d/html/103866.html" rel="external">"Treatment of rheumatoid arthritis in adults resistant to initial biologic DMARD therapy", section on 'Resistant to standard therapies'</a> and  <a class="medical medical_review" href="/d/html/5585.html" rel="external">"Cryopyrin-associated periodic syndromes and related disorders", section on 'Anakinra'</a> and  <a class="medical medical_review" href="/d/html/5597.html" rel="external">"The autoinflammatory diseases: An overview"</a> and  <a class="medical medical_review" href="/d/html/6400.html" rel="external">"Systemic juvenile idiopathic arthritis: Treatment", section on 'Interleukin 1 inhibitors'</a> and  <a class="medical medical_review" href="/d/html/4944.html" rel="external">"Recurrent pericarditis", section on 'Other immune therapy'</a> and  <a class="medical medical_review" href="/d/html/1666.html" rel="external">"Treatment of gout flares", section on 'Resistant or refractory disease'</a> and  <a class="medical medical_review" href="/d/html/5595.html" rel="external">"Treatment of adult-onset Still's disease", section on 'Canakinumab and rilonacept'</a>.)</p><p class="headingAnchor" id="H3499296949"><span class="h2">Canakinumab</span></p><p class="headingAnchor" id="H1604999534"><span class="h3">Structure and mechanism of action</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8906" href="/d/drug information/8906.html" rel="external">Canakinumab</a> is an immunoglobulin G1 (IgG1) monoclonal antibody against IL-1beta that blocks binding to the IL-1 receptor complex  (<a class="graphic graphic_figure graphicRef128248" href="/d/graphic/128248.html" rel="external">figure 1</a>). It does not bind IL-1alpha or IL-1ra. While antidrug antibodies may form with canakinumab use, they do not appear to block efficacy or correlate with adverse events [<a href="#rid31">31</a>].</p><p class="headingAnchor" id="H1340890283"><span class="h3">Indications</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8906" href="/d/drug information/8906.html" rel="external">Canakinumab</a> is approved by the FDA and European Medicines Agency for patients with CAPS, tumor necrosis factor receptor-associated periodic syndrome (TRAPS), hyperimmunoglobulin D syndrome (HIDS)/mevalonate kinase deficiency (MKD), familial Mediterranean fever (FMF), sJIA, and adult onset Still’s disease, and gout [<a href="#rid32">32,33</a>]. The uses of canakinumab for these and other indications and the evidence supporting such uses are described separately in the topic reviews on treatment of these disorders. (See  <a class="medical medical_review" href="/d/html/5585.html" rel="external">"Cryopyrin-associated periodic syndromes and related disorders", section on 'Canakinumab'</a> and  <a class="medical medical_review" href="/d/html/5580.html" rel="external">"Tumor necrosis factor receptor-1 associated periodic syndrome (TRAPS)", section on 'Frequent or poorly controlled symptoms and/or risk factors for amyloidosis'</a> and  <a class="medical medical_review" href="/d/html/5955.html" rel="external">"Hyperimmunoglobulin D syndrome: Management", section on 'IL-1 inhibition'</a> and  <a class="medical medical_review" href="/d/html/2574.html" rel="external">"Management of familial Mediterranean fever", section on 'Interleukin 1 inhibition'</a> and  <a class="medical medical_review" href="/d/html/6400.html" rel="external">"Systemic juvenile idiopathic arthritis: Treatment", section on 'Interleukin 1 inhibitors'</a> and  <a class="medical medical_review" href="/d/html/1666.html" rel="external">"Treatment of gout flares", section on 'Resistant or refractory disease'</a> and  <a class="medical medical_review" href="/d/html/5595.html" rel="external">"Treatment of adult-onset Still's disease", section on 'Canakinumab and rilonacept'</a>.)</p><p class="headingAnchor" id="H3199790999"><span class="h2">Rilonacept</span></p><p class="headingAnchor" id="H1941557230"><span class="h3">Structure and mechanism of action</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9483" href="/d/drug information/9483.html" rel="external">Rilonacept</a> is a synthetic protein composed of the extracellular domains of IL-1R1 and IL-1RAcP (two molecules of each) fused to a human IgG1 Fc domain  (<a class="graphic graphic_figure graphicRef128248" href="/d/graphic/128248.html" rel="external">figure 1</a>). By incorporating both components of the receptor, rilonacept is able to bind IL-1beta with an affinity approximately 100-fold that of surface IL-1R1, enabling it to serve as an effective soluble decoy receptor [<a href="#rid34">34</a>]. Affinity for IL-1alpha is comparable to or slightly lower than for IL-1beta, and for IL-1ra (the main natural antagonist of IL-1), 23-fold lower than for IL-1beta [<a href="#rid34">34</a>]. The equilibrium dissociation constants for rilonacept binding to IL-1beta, IL-1alpha, and IL-1ra are 0.5 pM, 1.4 pM, and 6.1 pM [<a href="#rid35">35</a>]. Antidrug antibodies may form with rilonacept use, some with neutralizing capacity in vitro, but no obvious correlation with respect to efficacy or adverse events has been observed [<a href="#rid36">36</a>]. The molecular weight of rilonacept is approximately 250 kDa.</p><p class="headingAnchor" id="H3667719369"><span class="h3">Indications</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9483" href="/d/drug information/9483.html" rel="external">Rilonacept</a> is approved by the FDA for patients with CAPS, recurrent pericarditis, and deficiency of the IL-1-receptor agonist (DIRA) [<a href="#rid35">35,37</a>]. The European Medicines Agency had previously approved rilonacept for CAPS, but approval was withdrawn by the sponsor [<a href="#rid38">38</a>]. Other indications for which rilonacept has shown promise are gout and sJIA [<a href="#rid37">37,39,40</a>]. The uses of rilonacept for these and other indications and the evidence supporting such uses are described separately in the topic reviews on treatment of these disorders. (See  <a class="medical medical_review" href="/d/html/5585.html" rel="external">"Cryopyrin-associated periodic syndromes and related disorders", section on 'Rilonacept'</a> and  <a class="medical medical_review" href="/d/html/1666.html" rel="external">"Treatment of gout flares", section on 'Resistant or refractory disease'</a> and  <a class="medical medical_review" href="/d/html/6400.html" rel="external">"Systemic juvenile idiopathic arthritis: Treatment", section on 'Interleukin 1 inhibitors'</a> and  <a class="medical medical_review" href="/d/html/5585.html" rel="external">"Cryopyrin-associated periodic syndromes and related disorders", section on 'Deficiency of the IL-1-receptor antagonist (DIRA)'</a> and  <a class="medical medical_review" href="/d/html/4944.html" rel="external">"Recurrent pericarditis", section on 'Interleukin 1 inhibitors'</a>.)</p><p class="headingAnchor" id="H2094192077"><span class="h1">ADVERSE EFFECTS</span><span class="headingEndMark"> — </span>The most commonly reported adverse effect in patients on interleukin (IL) 1 inhibitors is injection site reactions. Hepatitis is rare. There does not appear to a large increase in risk of serious infections overall, although patients with comorbidities and those on additional immunosuppressive agents may be at higher risk.</p><p class="headingAnchor" id="H3921352397"><span class="h2">Injection site reactions</span><span class="headingEndMark"> — </span>Injection site reactions tend to be mild and occur in most patients on <a class="drug drug_general" data-topicid="9246" href="/d/drug information/9246.html" rel="external">anakinra</a> [<a href="#rid41">41</a>], approximately 50 percent of patients on <a class="drug drug_general" data-topicid="9483" href="/d/drug information/9483.html" rel="external">rilonacept</a> [<a href="#rid35">35</a>], and approximately 10 percent of patients on <a class="drug drug_general" data-topicid="8906" href="/d/drug information/8906.html" rel="external">canakinumab</a> [<a href="#rid42">42</a>].</p><p>Patients receiving <a class="drug drug_general" data-topicid="9246" href="/d/drug information/9246.html" rel="external">anakinra</a> frequently report stinging, potentially related to the citrate buffer (pH 6.5) that prevents aggregation of recombinant IL-1 receptor antagonist (IL-1ra) [<a href="#rid41">41</a>]. More than 50 percent of patients experience a second kind of injection site reaction, wherein multiple prior injection sites simultaneously become red and painful  (<a class="graphic graphic_picture graphicRef139313" href="/d/graphic/139313.html" rel="external">picture 1</a>). Typically, this reaction occurs within the first month of therapy or not at all, and all but uniformly resolves within two months [<a href="#rid41">41</a>]. The basis for this reaction is unknown, but its transient course and failure to evolve into anaphylaxis suggest a nonallergic mechanism. Management of injection site reactions includes allowing the syringe to come to room temperature before injection, systemic antihistamines, and topical or occasionally low-dose systemic glucocorticoids. Patients should be warned in advance of this reaction to avoid unnecessary concern and reassured that the reaction passes without sequelae in the large majority of individuals.</p><p class="headingAnchor" id="H737904089"><span class="h2">Infection</span><span class="headingEndMark"> — </span>Despite the immune functions of IL-1alpha and IL-1beta, the impact of IL-1 inhibition on infection risk in human patients has been surprisingly modest. Overall, IL-1 inhibition exhibits relative safety, including in the setting of overt bacterial sepsis [<a href="#rid43">43-45</a>], although sustained use in patients with other comorbidities that predispose to infection likely results in increased risk.</p><p>A 2009 systematic review and meta-analysis of five randomized trials of <a class="drug drug_general" data-topicid="9246" href="/d/drug information/9246.html" rel="external">anakinra</a> involving 2876 patients with rheumatoid arthritis found that serious infections were numerically more common with anakinra than placebo (1.8 versus 0.6 percent), but this effect was not statistically significant [<a href="#rid46">46</a>]. No opportunistic infections (including tuberculosis) were noted, although rare infections with atypical pathogens have been observed at the case-report level [<a href="#rid47">47</a>]. Increased risk of severe infection was reported in a randomized trial when anakinra was combined with <a class="drug drug_general" data-topicid="8925" href="/d/drug information/8925.html" rel="external">etanercept</a> therapy (dosed once or twice weekly) in 244 patients with rheumatoid arthritis compared with etanercept alone (3.7, 7.4, and 0 percent, respectively) [<a href="#rid48">48</a>].</p><p>The <a class="drug drug_general" data-topicid="8906" href="/d/drug information/8906.html" rel="external">Canakinumab</a> Antiinflammatory Thrombosis Outcome Study (CANTOS) trial, which randomly assigned 10,061 adults with prior myocardial infarction to canakinumab or placebo, found that a reduction in risk for a second cardiovascular event was counterbalanced by an increase in death from infections (0.31 versus 0.18 events per 100 person-years), largely in patients who were older or had diabetes [<a href="#rid49">49</a>]. The incidence of tuberculosis was equivalent in the two groups. In trials of canakinumab for autoinflammatory diseases, neutropenia has been observed in several patients, and the rate of serious infections was 5.6 to 7.4 per 100 patient-years [<a href="#rid50">50</a>].</p><p>Adverse events from <a class="drug drug_general" data-topicid="9483" href="/d/drug information/9483.html" rel="external">rilonacept</a> include upper respiratory infections and neutropenia [<a href="#rid35">35</a>]. The rate of serious infections in patients on rilonacept is unknown.</p><p class="headingAnchor" id="H952521588"><span class="h2">Hepatitis</span><span class="headingEndMark"> — </span>Marked elevation of hepatic transaminases together with the appearance of inflammatory liver infiltrates, sometimes eosinophilic, has been reported rarely in patients receiving <a class="drug drug_general" data-topicid="9246" href="/d/drug information/9246.html" rel="external">anakinra</a> treatment [<a href="#rid14">14,51</a>]. Progression to symptomatic liver dysfunction with histologic foci of hepatocellular necrosis can occur [<a href="#rid52">52</a>]. Most reported patients have had systemic juvenile idiopathic arthritis (sJIA) or adult-onset Still's disease. Resolution with cessation of therapy and recurrence with rechallenge suggests a causative role for anakinra, although the basis for this effect is unknown [<a href="#rid14">14,53</a>]. Permanent liver injury has not been reported. Patients developing hepatitis on anakinra may be safely treated with other IL-1 antagonists.</p><p>Transaminase elevations (4 percent) have also been reported with <a class="drug drug_general" data-topicid="8906" href="/d/drug information/8906.html" rel="external">canakinumab</a>, although without reported progression to liver injury [<a href="#rid42">42</a>], and mild elevation of lipids are common in patients on <a class="drug drug_general" data-topicid="9483" href="/d/drug information/9483.html" rel="external">rilonacept</a> [<a href="#rid35">35</a>].</p><p class="headingAnchor" id="H3629490885"><span class="h2">Systemic juvenile idiopathic arthritis-associated lung disease</span><span class="headingEndMark"> — </span>Since the early 2000s, some patients with sJIA (up to 7 percent by one estimate) have been observed to develop inflammatory lung disease with high mortality [<a href="#rid54">54-56</a>]. The appearance of this disease complication coincident with expanded therapeutic use of IL-1 and IL-6 inhibition, including <a class="drug drug_general" data-topicid="9246" href="/d/drug information/9246.html" rel="external">anakinra</a> and <a class="drug drug_general" data-topicid="8906" href="/d/drug information/8906.html" rel="external">canakinumab</a>, has raised concerns for a causal relationship, particularly for IL-1 inhibition, although not all affected patients were exposed to cytokine inhibitors [<a href="#rid56">56</a>]. The etiologic relationship between cytokine antagonists and lung disease in sJIA remains unclear because some patients have stabilized and even improved while still receiving IL-1 inhibition [<a href="#rid55">55,57</a>]. An association has been noted between carriage of the human leukocyte antigen (HLA) allele DRB1*15 and development of allergic-type reactions to IL-1 blockade (as well as IL-6 blockade) in patients with sJIA, raising the possibility that these agents induce drug reaction with eosinophilia and systemic symptoms (DRESS) that could play a role in the development of sJIA lung disease [<a href="#rid58">58</a>]. However, this interpretation remains controversial; an alternate possibility (termed the cytokine plasticity hypothesis) is that the agents are not themselves antigenic but may contribute to immune-mediated Th2 reactions and lung pathology in the inflammatory context of sJIA [<a href="#rid59">59</a>]. (See  <a class="medical medical_review" href="/d/html/6413.html" rel="external">"Systemic juvenile idiopathic arthritis: Clinical manifestations and diagnosis", section on 'Other clinical findings'</a>.)</p><p class="headingAnchor" id="H3484879790"><span class="h1">ADDITIONAL DISTINCTIONS BETWEEN IL-1 INHIBITORS</span></p><p class="headingAnchor" id="H212014011"><span class="h2">Administration and half-life</span><span class="headingEndMark"> — </span>Practical considerations largely drive the clinical choice among IL-1 inhibitors including availability (insurance formularies, regulatory approval, and cost), mode of administration, and half-life. All three agents are administered by subcutaneous injection. <a class="drug drug_general" data-topicid="9246" href="/d/drug information/9246.html" rel="external">Anakinra</a> injections are daily and often sting. <a class="drug drug_general" data-topicid="8906" href="/d/drug information/8906.html" rel="external">Canakinumab</a> and <a class="drug drug_general" data-topicid="9483" href="/d/drug information/9483.html" rel="external">rilonacept</a> are injected less frequently (every one to two months and weekly, respectively), and injection site pain is less common, especially for canakinumab. However, the short half-life and rapid onset of action of anakinra represent major advantages for the use of anakinra in acutely ill patients and for diagnostic investigation of the role of IL-1 in a patient's illness, particularly given the documented safety of anakinra in the context of infection. As an example, we use anakinra in this "exploratory" capacity in the evaluation of patients with presumed systemic juvenile idiopathic arthritis (sJIA), in which fevers typically respond briskly to anakinra, as well as in the diagnostic evaluation in autoinflammatory disorders [<a href="#rid60">60,61</a>] (see  <a class="medical medical_review" href="/d/html/6413.html" rel="external">"Systemic juvenile idiopathic arthritis: Clinical manifestations and diagnosis"</a> and  <a class="medical medical_review" href="/d/html/6400.html" rel="external">"Systemic juvenile idiopathic arthritis: Treatment"</a> and  <a class="medical medical_review" href="/d/html/5597.html" rel="external">"The autoinflammatory diseases: An overview"</a>). The short half-life of anakinra also enables facile titration, including rapid tapering of patients in remission [<a href="#rid62">62</a>].</p><p class="headingAnchor" id="H1127664173"><span class="h2">Mechanism of action</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9246" href="/d/drug information/9246.html" rel="external">Anakinra</a> and <a class="drug drug_general" data-topicid="9483" href="/d/drug information/9483.html" rel="external">rilonacept</a> block both IL-1alpha and IL-1beta, while <a class="drug drug_general" data-topicid="8906" href="/d/drug information/8906.html" rel="external">canakinumab</a> blocks only IL-1beta. Because IL-1beta is dominant in systemic inflammatory diseases, this difference has not proven to represent a substantive difference between agents [<a href="#rid63">63</a>], although the unique functions of IL-1alpha raises the possibility that situations exist in which IL-1alpha inhibition could be an advantage (or a disadvantage).</p><p class="headingAnchor" id="H2104911605"><span class="h2">Potency</span><span class="headingEndMark"> — </span>The relative capacities of <a class="drug drug_general" data-topicid="9246" href="/d/drug information/9246.html" rel="external">anakinra</a>, <a class="drug drug_general" data-topicid="8906" href="/d/drug information/8906.html" rel="external">canakinumab</a>, and <a class="drug drug_general" data-topicid="9483" href="/d/drug information/9483.html" rel="external">rilonacept</a> to neutralize IL-1 signaling in vivo have never been compared directly. Anecdotally, patients who fail to respond to one may still respond to another. As an example, some patients with sJIA who have responded to canakinumab had previously received anakinra, although whether they had failed the latter agent due to lack of efficacy or because of intolerance of daily injections was unclear [<a href="#rid64">64</a>]. While comparison across studies is intrinsically problematic, the reported efficacy of rilonacept in familial Mediterranean fever (FMF), sJIA, and acute gout has been modest, suggesting underperformance relative to anakinra and canakinumab [<a href="#rid40">40,65,66</a>]. If genuine, this difference may reflect the fact that rilonacept neutralizes IL-1 receptor antagonist (IL-1ra) as well as IL-1alpha and IL-1beta.</p><p class="headingAnchor" id="H30549093"><span class="h2">Blood-brain barrier</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9246" href="/d/drug information/9246.html" rel="external">Anakinra</a> enters the cerebrospinal fluid, whereas blood-brain barrier penetration by <a class="drug drug_general" data-topicid="8906" href="/d/drug information/8906.html" rel="external">canakinumab</a> and <a class="drug drug_general" data-topicid="9483" href="/d/drug information/9483.html" rel="external">rilonacept</a> is undefined [<a href="#rid22">22</a>]. In cryopyrin-associated periodic syndromes (CAPS) patients with central nervous system inflammation, anakinra treatment was associated with lower cerebrospinal fluid white blood cell counts and IL-6 levels [<a href="#rid23">23</a>]. These findings suggest that anakinra is likely preferable for IL-1 inhibition in diseases characterized by inflammation in the brain and spinal cord.</p><p class="headingAnchor" id="H3824527179"><span class="h1">DISCONTINUING IL-1 INHIBITION</span><span class="headingEndMark"> — </span>Discontinuation of interleukin (IL) 1 inhibition is typically undertaken in patients who experience adverse events or inefficacy, or who are in clinical remission and may no longer need treatment. When discontinuing IL-1 inhibition, the substantially different half-lives of <a class="drug drug_general" data-topicid="9246" href="/d/drug information/9246.html" rel="external">anakinra</a> (4 to 6 hours), <a class="drug drug_general" data-topicid="8906" href="/d/drug information/8906.html" rel="external">canakinumab</a> (26 days), and <a class="drug drug_general" data-topicid="9483" href="/d/drug information/9483.html" rel="external">rilonacept</a> (7 days) result in highly divergent "off rates." IL-1beta induces its own production, so abrupt withdrawal of IL-1 inhibition has the potential to trigger a self-perpetuating inflammatory cycle, especially with anakinra, because of its short duration of action.</p><p>We taper <a class="drug drug_general" data-topicid="9246" href="/d/drug information/9246.html" rel="external">anakinra</a> by spacing injections to every other day, then every third day, followed by discontinuation.</p><p><a class="drug drug_general" data-topicid="8906" href="/d/drug information/8906.html" rel="external">Canakinumab</a> and <a class="drug drug_general" data-topicid="9483" href="/d/drug information/9483.html" rel="external">rilonacept</a> can be tapered by either the dose per injection or, more commonly, by spacing out the interval between administrations (for example, changing canakinumab injections from monthly to every two months then every three months before discontinuing altogether) [<a href="#rid67">67</a>].</p><p>For patients with conditions that are prone to abrupt and severe flares, such as systemic juvenile idiopathic arthritis (sJIA) and adult-onset Still's disease, we ask patients to maintain a supply of the IL-1 inhibitor on hand for ready reinitiation if needed.</p><p>Notably, the well-documented safety of <a class="drug drug_general" data-topicid="9246" href="/d/drug information/9246.html" rel="external">anakinra</a> in the setting of bacterial sepsis implies that, unlike most immunosuppressants, therapy should generally <strong>not</strong> be discontinued in patients experiencing acute infection [<a href="#rid43">43</a>]. Abrupt withdrawal in the setting of immune activation (for example, intercurrent viral or bacterial infection) has the potential to trigger an inflammatory spiral, especially in patients with sJIA and adult-onset Still's disease; in the context of infection, these patients may require more rather than less IL-1 inhibition to secure a positive outcome [<a href="#rid60">60,68</a>].</p><p class="headingAnchor" id="H492765478"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/120032.html" rel="external">"Society guideline links: Side effects of anti-inflammatory and anti-rheumatic drugs"</a>.)</p><p class="headingAnchor" id="H1432854190"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Roles of interleukin 1</strong> – Interleukin (IL) 1alpha and IL-1beta are potent proinflammatory cytokines involved in immune defense and in inflammatory diseases. IL-1beta typically predominates for systemic inflammation, while IL-1alpha plays a role primarily in local inflammation and in skin. (See <a class="local">'Overview of IL-1 biology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Types of IL-1 inhibitors</strong> – Three agents are available for pharmaceutical inhibition of IL-1: the recombinant IL-1 receptor antagonist (IL-1ra) <a class="drug drug_general" data-topicid="9246" href="/d/drug information/9246.html" rel="external">anakinra</a>; the anti-IL-1beta antibody <a class="drug drug_general" data-topicid="8906" href="/d/drug information/8906.html" rel="external">canakinumab</a>; and the IL-1 "trap" fusion molecule <a class="drug drug_general" data-topicid="9483" href="/d/drug information/9483.html" rel="external">rilonacept</a>. (See <a class="local">'Anakinra'</a> above and <a class="local">'Canakinumab'</a> above and <a class="local">'Rilonacept'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adverse effects</strong> – Pharmacologic inhibition of IL-1 is typically well tolerated. The most commonly reported adverse effect in patients on IL-1 inhibitors is injection site reactions. Hepatitis is rare. There does not appear to be a significant increased risk of serious infections overall. (See <a class="local">'Infection'</a> above and <a class="local">'Adverse effects'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Differences among IL-1 inhibitors that affect choice of which to use</strong> – The choice among IL-1 inhibitors integrates considerations including mode of administration, half-life, mechanism of action, potency, and penetration of the central nervous system. As an example, <a class="drug drug_general" data-topicid="9246" href="/d/drug information/9246.html" rel="external">anakinra</a> is administered by daily subcutaneous injection due to its short half-life, whereas <a class="drug drug_general" data-topicid="8906" href="/d/drug information/8906.html" rel="external">canakinumab</a> and <a class="drug drug_general" data-topicid="9483" href="/d/drug information/9483.html" rel="external">rilonacept</a> are administered by subcutaneous injection at longer intervals (every one to two months for canakinumab, weekly for rilonacept). (See <a class="local">'Additional distinctions between IL-1 inhibitors'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Discontinuing IL-1 inhibition</strong> – IL-1 inhibitors should be tapered gradually when discontinued. Unlike other immunosuppressive agents, discontinuation of IL-1 inhibitors in the context of infection is not required, both because they appear generally safe in this context and because serious flares of some IL-1-dependent inflammatory diseases may occur in the context of infection. (See <a class="local">'Discontinuing IL-1 inhibition'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Mantovani A, Dinarello CA, Molgora M, Garlanda C. Interleukin-1 and Related Cytokines in the Regulation of Inflammation and Immunity. Immunity 2019; 50:778.</a></li><li><a class="nounderline abstract_t">Jain A, Irizarry-Caro RA, McDaniel MM, et al. T cells instruct myeloid cells to produce inflammasome-independent IL-1β and cause autoimmunity. Nat Immunol 2020; 21:65.</a></li><li><a class="nounderline abstract_t">Donado CA, Cao AB, Simmons DP, et al. A Two-Cell Model for IL-1β Release Mediated by Death-Receptor Signaling. Cell Rep 2020; 31:107466.</a></li><li><a class="nounderline abstract_t">Rivers-Auty J, Daniels MJD, Colliver I, et al. Redefining the ancestral origins of the interleukin-1 superfamily. Nat Commun 2018; 9:1156.</a></li><li><a class="nounderline abstract_t">Cunin P, Nigrovic PA. Megakaryocytes as immune cells. J Leukoc Biol 2019; 105:1111.</a></li><li><a class="nounderline abstract_t">Kurt-Jones EA, Beller DI, Mizel SB, Unanue ER. Identification of a membrane-associated interleukin 1 in macrophages. Proc Natl Acad Sci U S A 1985; 82:1204.</a></li><li><a class="nounderline abstract_t">Kim B, Lee Y, Kim E, et al. The Interleukin-1α Precursor is Biologically Active and is Likely a Key Alarmin in the IL-1 Family of Cytokines. Front Immunol 2013; 4:391.</a></li><li><a class="nounderline abstract_t">Chen CJ, Kono H, Golenbock D, et al. Identification of a key pathway required for the sterile inflammatory response triggered by dying cells. Nat Med 2007; 13:851.</a></li><li><a class="nounderline abstract_t">Dayer JM, de Rochemonteix B, Burrus B, et al. Human recombinant interleukin 1 stimulates collagenase and prostaglandin E2 production by human synovial cells. J Clin Invest 1986; 77:645.</a></li><li><a class="nounderline abstract_t">Acosta-Rodriguez EV, Napolitani G, Lanzavecchia A, Sallusto F. Interleukins 1beta and 6 but not transforming growth factor-beta are essential for the differentiation of interleukin 17-producing human T helper cells. Nat Immunol 2007; 8:942.</a></li><li><a class="nounderline abstract_t">Ben-Sasson SZ, Hu-Li J, Quiel J, et al. IL-1 acts directly on CD4 T cells to enhance their antigen-driven expansion and differentiation. Proc Natl Acad Sci U S A 2009; 106:7119.</a></li><li><a class="nounderline abstract_t">Ben-Sasson SZ, Hogg A, Hu-Li J, et al. IL-1 enhances expansion, effector function, tissue localization, and memory response of antigen-specific CD8 T cells. J Exp Med 2013; 210:491.</a></li><li><a class="nounderline abstract_t">Jain A, Song R, Wakeland EK, Pasare C. T cell-intrinsic IL-1R signaling licenses effector cytokine production by memory CD4 T cells. Nat Commun 2018; 9:3185.</a></li><li class="breakAll">Anakinira (Updated July 5, 2017). In: LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet], National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda 2012-.</li><li><a class="nounderline abstract_t">Hannum CH, Wilcox CJ, Arend WP, et al. Interleukin-1 receptor antagonist activity of a human interleukin-1 inhibitor. Nature 1990; 343:336.</a></li><li><a class="nounderline abstract_t">Eisenberg SP, Evans RJ, Arend WP, et al. Primary structure and functional expression from complementary DNA of a human interleukin-1 receptor antagonist. Nature 1990; 343:341.</a></li><li><a class="nounderline abstract_t">Granowitz EV, Porat R, Mier JW, et al. Pharmacokinetics, safety and immunomodulatory effects of human recombinant interleukin-1 receptor antagonist in healthy humans. Cytokine 1992; 4:353.</a></li><li><a class="nounderline abstract_t">Fields JK, Günther S, Sundberg EJ. Structural Basis of IL-1 Family Cytokine Signaling. Front Immunol 2019; 10:1412.</a></li><li><a class="nounderline abstract_t">Arend WP, Welgus HG, Thompson RC, Eisenberg SP. Biological properties of recombinant human monocyte-derived interleukin 1 receptor antagonist. J Clin Invest 1990; 85:1694.</a></li><li><a class="nounderline abstract_t">Wikén M, Hallén B, Kullenberg T, Koskinen LO. Development and effect of antibodies to anakinra during treatment of severe CAPS: sub-analysis of a long-term safety and efficacy study. Clin Rheumatol 2018; 37:3381.</a></li><li><a class="nounderline abstract_t">Ilowite N, Porras O, Reiff A, et al. Anakinra in the treatment of polyarticular-course juvenile rheumatoid arthritis: safety and preliminary efficacy results of a randomized multicenter study. Clin Rheumatol 2009; 28:129.</a></li><li><a class="nounderline abstract_t">Goldbach-Mansky R, Dailey NJ, Canna SW, et al. Neonatal-onset multisystem inflammatory disease responsive to interleukin-1beta inhibition. N Engl J Med 2006; 355:581.</a></li><li><a class="nounderline abstract_t">Rodriguez-Smith J, Lin YC, Tsai WL, et al. Cerebrospinal Fluid Cytokines Correlate With Aseptic Meningitis and Blood-Brain Barrier Function in Neonatal-Onset Multisystem Inflammatory Disease: Central Nervous System Biomarkers in Neonatal-Onset Multisystem Inflammatory Disease Correlate With Central Nervous System Inflammation. Arthritis Rheumatol 2017; 69:1325.</a></li><li class="breakAll">Anakinra. US Food and Drug Administration (FDA) approved product information. Revised December 2012. US FDA. (Available online at https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/103950s5136lbl.pdf (Accessed April 21, 2020)).</li><li class="breakAll">Anakinra. European Medicines Agency (EMA) Summary of product characteristics. Last updated March 14, 2019. European Medicines Agency. (Available online at https://www.ema.europa.eu/en/documents/product-information/kineret-epar-product-information_en.pdf (Accessed April 21, 2020)).</li><li><a class="nounderline abstract_t">Brucato A, Imazio M, Gattorno M, et al. Effect of Anakinra on Recurrent Pericarditis Among Patients With Colchicine Resistance and Corticosteroid Dependence: The AIRTRIP Randomized Clinical Trial. JAMA 2016; 316:1906.</a></li><li><a class="nounderline abstract_t">Ter Haar NM, Eijkelboom C, Cantarini L, et al. Clinical characteristics and genetic analyses of 187 patients with undefined autoinflammatory diseases. Ann Rheum Dis 2019; 78:1405.</a></li><li><a class="nounderline abstract_t">So A, De Smedt T, Revaz S, Tschopp J. A pilot study of IL-1 inhibition by anakinra in acute gout. Arthritis Res Ther 2007; 9:R28.</a></li><li><a class="nounderline abstract_t">Loustau C, Rosine N, Forien M, et al. Effectiveness and safety of anakinra in gout patients with stage 4-5 chronic kidney disease or kidney transplantation: A multicentre, retrospective study. Joint Bone Spine 2018; 85:755.</a></li><li><a class="nounderline abstract_t">Janssen CA, Oude Voshaar MAH, Vonkeman HE, et al. Anakinra for the treatment of acute gout flares: a randomized, double-blind, placebo-controlled, active-comparator, non-inferiority trial. Rheumatology (Oxford) 2019.</a></li><li><a class="nounderline abstract_t">Sun H, Van LM, Floch D, et al. Pharmacokinetics and Pharmacodynamics of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis. J Clin Pharmacol 2016; 56:1516.</a></li><li class="breakAll">Canakinumab. European Medicines Agency (EMA) Summary of product characteristics. European Medicines Agency. https://www.ema.europa.eu/en/documents/product-information/ilaris-epar-product-information_en.pdf (Accessed on October 11, 2023).</li><li class="breakAll">Canakinumab injection, solution. US Food and Drug Administration (FDA) approved product information. Revised August 25, 2023. US National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7d271f3b-e4f9-4d80-8dcf-28d49123f80e.</li><li><a class="nounderline abstract_t">Economides AN, Carpenter LR, Rudge JS, et al. Cytokine traps: multi-component, high-affinity blockers of cytokine action. Nat Med 2003; 9:47.</a></li><li class="breakAll">Rilonacept. lUS Food and Drug Administration approved product information. Revised 03/2021. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125249s049lbl.pdf (Accessed on October 04, 2021).</li><li><a class="nounderline abstract_t">McDermott MF. Rilonacept in the treatment of chronic inflammatory disorders. Drugs Today (Barc) 2009; 45:423.</a></li><li><a class="nounderline abstract_t">Garg M, de Jesus AA, Chapelle D, et al. Rilonacept maintains long-term inflammatory remission in patients with deficiency of the IL-1 receptor antagonist. JCI Insight 2017; 2.</a></li><li class="breakAll">Rilonacept. European Medicines Agency (EMA) Summary of product characteristics. Last updated September 24, 2012. European Medicines Agency. (Available online at https://www.ema.europa.eu/en/documents/product-information/rilonacept-regeneron-epar-product-information_en.pdf (Accessed April 21, 2020)).</li><li><a class="nounderline abstract_t">Schumacher HR Jr, Sundy JS, Terkeltaub R, et al. Rilonacept (interleukin-1 trap) in the prevention of acute gout flares during initiation of urate-lowering therapy: results of a phase II randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2012; 64:876.</a></li><li><a class="nounderline abstract_t">Ilowite NT, Prather K, Lokhnygina Y, et al. Randomized, double-blind, placebo-controlled trial of the efficacy and safety of rilonacept in the treatment of systemic juvenile idiopathic arthritis. Arthritis Rheumatol 2014; 66:2570.</a></li><li><a class="nounderline abstract_t">Kaiser C, Knight A, Nordström D, et al. Injection-site reactions upon Kineret (anakinra) administration: experiences and explanations. Rheumatol Int 2012; 32:295.</a></li><li class="breakAll">Canakinumab. US Food and Drug Administration (FDA) approved product information. Revised September 2016. US Food and Drug Administration (Available online at https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/BLA125319_858687lbl.pdf (Accessed April 21, 2020)).</li><li><a class="nounderline abstract_t">Fisher CJ Jr, Dhainaut JF, Opal SM, et al. Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double-blind, placebo-controlled trial. Phase III rhIL-1ra Sepsis Syndrome Study Group. JAMA 1994; 271:1836.</a></li><li><a class="nounderline abstract_t">Opal SM, Fisher CJ Jr, Dhainaut JF, et al. Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. The Interleukin-1 Receptor Antagonist Sepsis Investigator Group. Crit Care Med 1997; 25:1115.</a></li><li><a class="nounderline abstract_t">Shakoory B, Carcillo JA, Chatham WW, et al. Interleukin-1 Receptor Blockade Is Associated With Reduced Mortality in Sepsis Patients With Features of Macrophage Activation Syndrome: Reanalysis of a Prior Phase III Trial. Crit Care Med 2016; 44:275.</a></li><li><a class="nounderline abstract_t">Mertens M, Singh JA. Anakinra for rheumatoid arthritis. Cochrane Database Syst Rev 2009; :CD005121.</a></li><li><a class="nounderline abstract_t">Furst DE. The risk of infections with biologic therapies for rheumatoid arthritis. Semin Arthritis Rheum 2010; 39:327.</a></li><li><a class="nounderline abstract_t">Genovese MC, Cohen S, Moreland L, et al. Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate. Arthritis Rheum 2004; 50:1412.</a></li><li><a class="nounderline abstract_t">Ridker PM, Everett BM, Thuren T, et al. Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. N Engl J Med 2017; 377:1119.</a></li><li><a class="nounderline abstract_t">De Benedetti F, Gattorno M, Anton J, et al. Canakinumab for the Treatment of Autoinflammatory Recurrent Fever Syndromes. N Engl J Med 2018; 378:1908.</a></li><li><a class="nounderline abstract_t">Canna S, Frankovich J, Higgins G, et al. Acute hepatitis in three patients with systemic juvenile idiopathic arthritis taking interleukin-1 receptor antagonist. Pediatr Rheumatol Online J 2009; 7:21.</a></li><li><a class="nounderline abstract_t">Taylor SA, Vittorio JM, Martinez M, et al. Anakinra-Induced Acute Liver Failure in an Adolescent Patient with Still's Disease. Pharmacotherapy 2016; 36:e1.</a></li><li><a class="nounderline abstract_t">Shah P, Sundaram V, Björnsson E. Biologic and Checkpoint Inhibitor-Induced Liver Injury: A Systematic Literature Review. Hepatol Commun 2020; 4:172.</a></li><li><a class="nounderline abstract_t">Kimura Y, Weiss JE, Haroldson KL, et al. Pulmonary hypertension and other potentially fatal pulmonary complications in systemic juvenile idiopathic arthritis. Arthritis Care Res (Hoboken) 2013; 65:745.</a></li><li><a class="nounderline abstract_t">Schulert GS, Yasin S, Carey B, et al. Systemic Juvenile Idiopathic Arthritis-Associated Lung Disease: Characterization and Risk Factors. Arthritis Rheumatol 2019; 71:1943.</a></li><li><a class="nounderline abstract_t">Saper VE, Chen G, Deutsch GH, et al. Emergent high fatality lung disease in systemic juvenile arthritis. Ann Rheum Dis 2019; 78:1722.</a></li><li><a class="nounderline abstract_t">Nigrovic PA. Storm Warning: Lung Disease in Systemic Juvenile Idiopathic Arthritis. Arthritis Rheumatol 2019; 71:1773.</a></li><li><a class="nounderline abstract_t">Saper VE, Ombrello MJ, Tremoulet AH, et al. Severe delayed hypersensitivity reactions to IL-1 and IL-6 inhibitors link to common HLA-DRB1*15 alleles. Ann Rheum Dis 2022; 81:406.</a></li><li><a class="nounderline abstract_t">Binstadt BA, Nigrovic PA. The Conundrum of Lung Disease and Drug Hypersensitivity-like Reactions in Systemic Juvenile Idiopathic Arthritis. Arthritis Rheumatol 2022; 74:1122.</a></li><li><a class="nounderline abstract_t">Nigrovic PA, Mannion M, Prince FH, et al. Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis: report of forty-six patients from an international multicenter series. Arthritis Rheum 2011; 63:545.</a></li><li><a class="nounderline abstract_t">Nigrovic PA, Lee PY, Hoffman HM. Monogenic autoinflammatory disorders: Conceptual overview, phenotype, and clinical approach. J Allergy Clin Immunol 2020; 146:925.</a></li><li><a class="nounderline abstract_t">Ter Haar NM, van Dijkhuizen EHP, Swart JF, et al. Treatment to Target Using Recombinant Interleukin-1 Receptor Antagonist as First-Line Monotherapy in New-Onset Systemic Juvenile Idiopathic Arthritis: Results From a Five-Year Follow-Up Study. Arthritis Rheumatol 2019; 71:1163.</a></li><li><a class="nounderline abstract_t">Dinarello CA. The IL-1 family of cytokines and receptors in rheumatic diseases. Nat Rev Rheumatol 2019; 15:612.</a></li><li><a class="nounderline abstract_t">Ruperto N, Brunner HI, Quartier P, et al. Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis. N Engl J Med 2012; 367:2396.</a></li><li><a class="nounderline abstract_t">Hashkes PJ, Spalding SJ, Giannini EH, et al. Rilonacept for colchicine-resistant or -intolerant familial Mediterranean fever: a randomized trial. Ann Intern Med 2012; 157:533.</a></li><li><a class="nounderline abstract_t">Terkeltaub RA, Schumacher HR, Carter JD, et al. Rilonacept in the treatment of acute gouty arthritis: a randomized, controlled clinical trial using indomethacin as the active comparator. Arthritis Res Ther 2013; 15:R25.</a></li><li><a class="nounderline abstract_t">Quartier P, Alexeeva E, Constantin T, et al. Tapering Canakinumab Monotherapy in Patients With Systemic Juvenile Idiopathic Arthritis in Clinical Remission: Results From a Phase IIIb/IV Open-Label, Randomized Study. Arthritis Rheumatol 2021; 73:336.</a></li><li><a class="nounderline abstract_t">Eloseily EM, Weiser P, Crayne CB, et al. Benefit of Anakinra in Treating Pediatric Secondary Hemophagocytic Lymphohistiocytosis. Arthritis Rheumatol 2020; 72:326.</a></li></ol></div><div id="topicVersionRevision">Topic 127997 Version 14.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30995499" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Interleukin-1 and Related Cytokines in the Regulation of Inflammation and Immunity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31848486" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : T cells instruct myeloid cells to produce inflammasome-independent IL-1βand cause autoimmunity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32268091" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : A Two-Cell Model for IL-1βRelease Mediated by Death-Receptor Signaling.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29559685" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Redefining the ancestral origins of the interleukin-1 superfamily.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30645026" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Megakaryocytes as immune cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3919388" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Identification of a membrane-associated interleukin 1 in macrophages.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24312098" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : The Interleukin-1αPrecursor is Biologically Active and is Likely a Key Alarmin in the IL-1 Family of Cytokines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17572686" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Identification of a key pathway required for the sterile inflammatory response triggered by dying cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3003163" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Human recombinant interleukin 1 stimulates collagenase and prostaglandin E2 production by human synovial cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17676045" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Interleukins 1beta and 6 but not transforming growth factor-beta are essential for the differentiation of interleukin 17-producing human T helper cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19359475" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : IL-1 acts directly on CD4 T cells to enhance their antigen-driven expansion and differentiation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23460726" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : IL-1 enhances expansion, effector function, tissue localization, and memory response of antigen-specific CD8 T cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30093707" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : T cell-intrinsic IL-1R signaling licenses effector cytokine production by memory CD4 T cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30093707" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : T cell-intrinsic IL-1R signaling licenses effector cytokine production by memory CD4 T cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2137200" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Interleukin-1 receptor antagonist activity of a human interleukin-1 inhibitor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2137201" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Primary structure and functional expression from complementary DNA of a human interleukin-1 receptor antagonist.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1420996" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Pharmacokinetics, safety and immunomodulatory effects of human recombinant interleukin-1 receptor antagonist in healthy humans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31281320" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Structural Basis of IL-1 Family Cytokine Signaling.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2139669" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Biological properties of recombinant human monocyte-derived interleukin 1 receptor antagonist.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29982913" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Development and effect of antibodies to anakinra during treatment of severe CAPS: sub-analysis of a long-term safety and efficacy study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18766426" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Anakinra in the treatment of polyarticular-course juvenile rheumatoid arthritis: safety and preliminary efficacy results of a randomized multicenter study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16899778" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Neonatal-onset multisystem inflammatory disease responsive to interleukin-1beta inhibition.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28118536" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Cerebrospinal Fluid Cytokines Correlate With Aseptic Meningitis and Blood-Brain Barrier Function in Neonatal-Onset Multisystem Inflammatory Disease: Central Nervous System Biomarkers in Neonatal-Onset Multisystem Inflammatory Disease Correlate With Central Nervous System Inflammation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28118536" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Cerebrospinal Fluid Cytokines Correlate With Aseptic Meningitis and Blood-Brain Barrier Function in Neonatal-Onset Multisystem Inflammatory Disease: Central Nervous System Biomarkers in Neonatal-Onset Multisystem Inflammatory Disease Correlate With Central Nervous System Inflammation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28118536" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Cerebrospinal Fluid Cytokines Correlate With Aseptic Meningitis and Blood-Brain Barrier Function in Neonatal-Onset Multisystem Inflammatory Disease: Central Nervous System Biomarkers in Neonatal-Onset Multisystem Inflammatory Disease Correlate With Central Nervous System Inflammation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27825009" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Effect of Anakinra on Recurrent Pericarditis Among Patients With Colchicine Resistance and Corticosteroid Dependence: The AIRTRIP Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31278138" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Clinical characteristics and genetic analyses of 187 patients with undefined autoinflammatory diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17352828" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : A pilot study of IL-1 inhibition by anakinra in acute gout.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29654950" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Effectiveness and safety of anakinra in gout patients with stage 4-5 chronic kidney disease or kidney transplantation: A multicentre, retrospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30602035" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Anakinra for the treatment of acute gout flares: a randomized, double-blind, placebo-controlled, active-comparator, non-inferiority trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27119439" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Pharmacokinetics and Pharmacodynamics of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27119439" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Pharmacokinetics and Pharmacodynamics of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27119439" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Pharmacokinetics and Pharmacodynamics of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12483208" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Cytokine traps: multi-component, high-affinity blockers of cytokine action.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12483208" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Cytokine traps: multi-component, high-affinity blockers of cytokine action.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19649332" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Rilonacept in the treatment of chronic inflammatory disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28814674" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Rilonacept maintains long-term inflammatory remission in patients with deficiency of the IL-1 receptor antagonist.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28814674" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Rilonacept maintains long-term inflammatory remission in patients with deficiency of the IL-1 receptor antagonist.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22223180" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Rilonacept (interleukin-1 trap) in the prevention of acute gout flares during initiation of urate-lowering therapy: results of a phase II randomized, double-blind, placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24839206" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Randomized, double-blind, placebo-controlled trial of the efficacy and safety of rilonacept in the treatment of systemic juvenile idiopathic arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21881988" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Injection-site reactions upon Kineret (anakinra) administration: experiences and explanations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21881988" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Injection-site reactions upon Kineret (anakinra) administration: experiences and explanations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8196140" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double-blind, placebo-controlled trial. Phase III rhIL-1ra Sepsis Syndrome Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9233735" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. The Interleukin-1 Receptor Antagonist Sepsis Investigator Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26584195" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Interleukin-1 Receptor Blockade Is Associated With Reduced Mortality in Sepsis Patients With Features of Macrophage Activation Syndrome: Reanalysis of a Prior Phase III Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19160248" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Anakinra for rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19117595" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : The risk of infections with biologic therapies for rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15146410" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28845751" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29768139" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Canakinumab for the Treatment of Autoinflammatory Recurrent Fever Syndromes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20028520" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Acute hepatitis in three patients with systemic juvenile idiopathic arthritis taking interleukin-1 receptor antagonist.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26749403" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Anakinra-Induced Acute Liver Failure in an Adolescent Patient with Still's Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32025603" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Biologic and Checkpoint Inhibitor-Induced Liver Injury: A Systematic Literature Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23139240" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Pulmonary hypertension and other potentially fatal pulmonary complications in systemic juvenile idiopathic arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31379071" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Systemic Juvenile Idiopathic Arthritis-Associated Lung Disease: Characterization and Risk Factors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31562126" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Emergent high fatality lung disease in systemic juvenile arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31390168" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Storm Warning: Lung Disease in Systemic Juvenile Idiopathic Arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34789453" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Severe delayed hypersensitivity reactions to IL-1 and IL-6 inhibitors link to common HLA-DRB1*15 alleles.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35413159" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : The Conundrum of Lung Disease and Drug Hypersensitivity-like Reactions in Systemic Juvenile Idiopathic Arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21280009" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis: report of forty-six patients from an international multicenter series.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33160483" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Monogenic autoinflammatory disorders: Conceptual overview, phenotype, and clinical approach.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30848528" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Treatment to Target Using Recombinant Interleukin-1 Receptor Antagonist as First-Line Monotherapy in New-Onset Systemic Juvenile Idiopathic Arthritis: Results From a Five-Year Follow-Up Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31515542" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : The IL-1 family of cytokines and receptors in rheumatic diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23252526" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23070486" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Rilonacept for colchicine-resistant or -intolerant familial Mediterranean fever: a randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23375025" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Rilonacept in the treatment of acute gouty arthritis: a randomized, controlled clinical trial using indomethacin as the active comparator.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32783351" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Tapering Canakinumab Monotherapy in Patients With Systemic Juvenile Idiopathic Arthritis in Clinical Remission: Results From a Phase IIIb/IV Open-Label, Randomized Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31513353" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Benefit of Anakinra in Treating Pediatric Secondary Hemophagocytic Lymphohistiocytosis.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
